Keywords ICP monitoring . Naloxone-precipitated opiate withdrawal . Acute alcohol withdrawal . Acetaminophen-induced acute liver failure . Public health Background: The approach to management of paracetamol (acetaminophen (APAP)) poisoning is different in the UK following a 2012 decision by the Commission on Human Medicines (CHM) to lower the threshold for N-acetylcysteine (NAC) treatment from the B200 mg/L^(200 μg/mL) nomogram line to the B100 mg/L^line. The CHM also recommended reducing the rate of initial infusion from 15 to 60 min in an attempt to reduce adverse drug reactions (ADRs). Research Question: What effect have the CHM changes concerning the use of NAC for APAP toxicity had on the presentation, admission, treatment, adverse reactions, and health-care costs of APAP poisoning in the UK? Methods: This was a prospective cohort study of adult patients presenting to three large specialty hospitals (with toxicology units) with APAP overdose over a 2-year period (9/4/ 11 through 9/3/13). This time period involved consecutive calendar years including the years immediately preceding and immediately succeeding the implementation of the new CHM recommendations. Patients who were evaluated and discharged from the emergency department and those admitted for APAP toxicity were included. Eligible patients included those with any of the following ingestion histories: (1) >4 g of APAP (alone or in combination with other drugs) as a single ingestion or over any 24-h period, (2) <4 g of APAP but when blood results indicated the need for NAC, or (3) ingestions of an unknown amount of APAP. At one site, 150 treated patients were excluded from ADR analysis due to recruitment into a separate antiemetic trial (doi:10.1016/S0140-6736(13)62062-0). During the second half of the study period (9/3/12), patients received NAC for a lower APAP concentration (B100 mg/L^nomogram line instead of the B200 mg/Ll ine) and at a slower loading rate (150 mg/kg IV over 60 min instead of 15).
CHM recommendations. Patients who were evaluated and discharged from the emergency department and those admitted for APAP toxicity were included. Eligible patients included those with any of the following ingestion histories: (1) >4 g of APAP (alone or in combination with other drugs) as a single ingestion or over any 24-h period, (2) <4 g of APAP but when blood results indicated the need for NAC, or (3) ingestions of an unknown amount of APAP. At one site, 150 treated patients were excluded from ADR analysis due to recruitment into a separate antiemetic trial (doi:10.1016/S0140-6736(13)62062-0). During the second half of the study period (9/3/12), patients received NAC for a lower APAP concentration (B100 mg/L^nomogram line instead of the B200 mg/Ll ine) and at a slower loading rate (150 mg/kg IV over 60 min instead of 15).
Costs were estimated from National Health Service (NHS) databanks using NHS financial year 2011-12 reference costs for three different diagnostic groups: those discharged without NAC treatment, those admitted without NAC treatment, and those admitted with NAC treatment. The rates of ADRs were calculated based on the use of medications (e.g., anti-emetics, antihistamines, and bronchodilators) typically used to treat ADRs from NAC. Results: A total of 1703 patients presented in the year before the CHM changes and 1854 in the year after. There was a relative increase of 8.9 % for year 2. More patients were treated with NAC following the change in recommendations: 626/1703 [36.8 %] The calculated full annual cost of managing APAP overdose was £40.0 million before the change and £48.3 million afterwards, absolute annual increase of £8.3 million (95 % CI 6.4 to 10.2 million). Conclusion: The CHM changes have increased the numbers of patients admitted to hospital and treated with NAC without affecting ADRs. Since the cost increase was significant, a formal safety and cost-benefit review of the CHM guidance is indicated. Critique: Data came from three specialty centers and may not reflect what is done at other sites. The cost calculations did not account for any potential cost reduction as a result of fewer cases of severe hepatic injury in patients who would have been untreated using the previous management guidelines. The method for detecting ADRs was suboptimal and only involved one site. Lastly, there appeared to be a statistically significant difference in outcomes between the three sites. Implication for Toxicologists: This study described the exorbitant total cost per Bexpected^life saved when reducing the treatment threshold from an APAP level of 200 to 100 mg/L. It also suggested no reduction in ADRs by slowing the NAC loading dose infusion from 15 to 60 min. Background: Symptom-driven treatment of alcohol withdrawal syndrome (AWS) with benzodiazepines is the cornerstone of therapy. However, benzodiazepines may cause sedation and respiratory suppression possibly resulting in the need for mechanical ventilation. Dexmedetomidine (DEX), an α-2 receptor agonist, may be uniquely suited for a role in the treatment of AWS as it controls hyperadrenergic symptoms with minimal risk of respiratory suppression. Research Question: What is the efficacy of DEX, as measured by benzodiazepine requirement and agitation scores, in the treatment of severe AWS? Methods: This was a prospective, randomized, double-blind, placebo-controlled trial set in the medical intensive care unit (ICU) of a single urban academic center. Adult patients between the ages of 18 and 85 years of age receiving standard therapy (symptom-triggered benzodiazepines) for Bsevere AWS^were eligible for inclusion. Severe AWS was defined as a Clinical Institute Withdrawal Assessment (CIWA) score of ≥15 despite receiving ≥16 mg of intravenous (IV) lorazepam within a 4-h period. There were numerous exclusion criteria. Subjects were block-randomized to receive either DEX 1.2 μg/kg/h (high dose (HD)) and 0.4 μg/kg/h (low dose (LD)) or placebo as adjunctive therapy to the AWS protocol (symptom-triggered benzodiazepines). Benzodiazepines and phenobarbital (but not propofol) were converted to lorazepam equivalents. The use of analgesic and antipsychotic medications were also recorded. Results: A total of 24 patients were enrolled, eight in each group. High-and low-dose DEX groups were combined for primary analysis. The difference in 24-h lorazepam requirements prior to study drug compared with 24-h post-study drug was statistically lower in the DEX group (−56.4 mg, interquartile range (IQR) −16.8 to −94.5) vs. placebo (−8 mg, IQR −31.3 to −76.2); p=0.037. Median differences were similar for the HD and LD groups. The 7-day cumulative lorazepam requirements were not statistically different between the DEX and placebo groups: 159 vs. 181 mg. Within 24 h, CIWA or Riker scale (for intubated patients) scores were similar between the DEX and placebo groups for severe (13 vs. 25 %) and moderate agitation (27 vs. 22 %), respectively. The use of an opiate or antipsychotic was similar between the placebo and combined DEX groups. Bradycardia (heart rate <50 beats/min) and hypotension (mean arterial pressure <65 mmHg or systolic pressure <90 mmHg) occurred more frequently in the DEX group (HD>LD) but due to small group sizes were not statistically significant. Neither intubation nor seizure occurred in any patient after enrollment. Conclusion: Adjunctive DEX for severe AWS demonstrated a statistically significant reduction in lorazepam requirement in the first 24 h without compromising symptom control. Critique: This was a small study (n=24), and only 10 % of assessed patients (n=233) were included. There were statistical differences between the groups in terms of baseline (preenrollment) health status and the amount of lorazepam received in the 24-h prior to study initiation. The median time from enrollment to study drug initiation was >13 h for both DEX groups and may have biased the results against DEX. Nearly half of the study participants (45.8 %) were intubated at the time of enrollment. Although the investigators had planned a priori to use Riker scores (if CIWA was absent or the patient was intubated), there is no correlation between the scales. The fact that no patients seized or required intubation after enrollment suggests against the accuracy of labeling these patients as having Bsevere^withdrawal. The exclusion criteria limit validation of these findings to a majority of ICU patients with concurrent alcohol withdrawal. Implication for Toxicologists: Although benzodiazepines are the mainstay of AWS treatment, there may be a role for DEX in specific patients. It is important for toxicologists to remind our ICU partners that DEX can sedate patients in alcohol withdrawal (and blunt signs of worsening withdrawal such as tachycardia) but does not raise seizure threshold. The optimal patient selection and dosing for DEX in alcohol withdrawal are yet to be determined. Background: Physiological stress is a common risk factor for both cardiovascular disorders and substance abuse. Chronic opiate abuse may introduce systemic stress that mimics cardiovascular disease by increasing noradrenergic and hypothalamic-pituitary axis (HPA) pathways. These stress response pathways are medicated by norepinephrine, corticotropin-releasing factor (CRF), and adrenocorticotropic hormone (ACTH). The CRF1 receptor is upregulated in the right ventricle during cardiac disease states. Acute naloxoneinduced opiate withdrawal has been associated with cardiac dysfunction without a clear mechanistic etiology. Research Question: Is there a physiologic link between opiate dependence and right ventricular CFR1 receptor activity and how are the behavioral and physiological features of naloxone-precipitated withdrawal mitigated by pre-treatment with the CRF1 receptor antagonist CP-154,526 (CP)? Methods: Interventions included the use of naloxone and/ or pre-treatment with CP. Saline and the CP Bvehicle( without CP) served as control interventions respectively. Male Sprague-Dawley rats were divided into morphinehabituated and placebo (control) groups. Animals in each of these two groups were then subdivided into one of four study arms: (1) vehicle + saline, (2) CP pre-treatment+saline, (3) vehicle+naloxone, and (4) CP pre-treatment+ naloxone. The rats were observed 60 min postinfusion for behavioral changes and then sacrificed for measurement of ACTH and corticosterone plasma concentrations (markers of systemic stress). Right ventricular tissue was collected to measure tissue concentrations of norepinephrine (NE), normetanephrine (NMN; NE metabolite), tyrosine hydroxylase (TH; catalyst for the rate limiting step in catecholamine synthesis), and phosphorylated extracellular signal-regulated kinase 1 and 2 (phospho-ERK1 and 2; markers of cardiac sympathetic activity). Results: A total of 69 animals were studied: 35 in the morphine group and 34 controls. Antagonism of CRF1 receptors by CP prevented the development of behavioral signs of withdrawal in all morphine-habituated rats. All morphine-habituated rats that received naloxone (groups 3 and 4) had statistically significant elevations in plasma ACTH, corticosterone, and right ventricular TH and phospho-ERK1 and 2. However, these elevations were significantly less in group 4 (CP pre-treatment + naloxone). Additionally, while rats in group 3 showed no change in ventricular NE, they had significant increase in NMN, suggesting high tissue turnover of NE. Rats in group 4 showed no elevation in NE or NMN compared to controls. Conclusions: CRF activation and right ventricular CRF1 receptor activity are involved in cardiac adaptive changes seen in morphine dependence and may contribute to stress-induced cardiovascular dysfunction in acute opiate withdrawal. Pre-treatment with a CRF1 receptor antagonist may prevent the development of behavioral and autonomic dysfunction in naloxone-induced opiate withdrawal. Critique: Grossly, the conclusions appear to be somewhat obvious: naloxone-induced morphine withdrawal is a systemically stressful event. The receptor level changes identified in the right ventricle connecting morphine habituation to changes seen in cardiovascular disease are interesting but (perhaps) limited to the fact that a single receptor is associated with significant systemic effects following the induction of withdrawal. The authors' conclusion that CRF1 activation may contribute to naloxone-induced cardiovascular dysfunction may be overstated due to no direct measurements of cardiac function. Implications for Toxicologists: The heretofore nebulous connection between naloxone-induced opiate withdrawal and cardiac dysfunction may now be linked mechanistically to a specifically identified receptor. Alone, naloxone does not seem to induce a physiologic or local cardiac stress response. Methods: This was a retrospective cohort analysis of patients with grade III or IV hepatic encephalopathy at academic liver transplant centers. Patients with cirrhosis, acute-on-chronic liver failure, and <18 years of age were excluded. Data were collected prospectively through the US Acute Liver Failure
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